LYMPHOMAS

Dr Salles provides an overview of the available third-line treatment options for patients with R/R DLBCL who are ineligible for or do not wish to receive autologous stem cell transplant or CAR T-cell therapy.

An oncologist describes the typical major challenges of managing patients with R/R DLBCL and the incidence of relapsed or refractory disease.

Gilles Salles, MD, PhD, presents the case of a 51-year-old woman with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Findings from a phase 1 study concluded zandelisib given to patients with relapsed/refractory B-cell malignancies at 60 mg once daily in an intermittent dosing schedule reflected in a positive safety profile.

Manali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.

Many clinicians believe the most significant advance in LBCL treatment in this time is the development of chimeric antigen receptor T-cell therapy.

Dr Matthew Lunning closes his discussion on DLBCL by highlighting unmet needs in the treatment landscape.

Matthew Lunning, DO, FACP, shares data from the RE-MIND2 trial and explains how it compares to the L-MIND trial.

The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

A review of the methods and data from a clinical trial investigating a combination therapy for relapsed/refractory DLBCL.

Dr Matthew Lunning describes the available third- and subsequent-line treatments for patients with relapsed/refractory DLBCL (R/R DLBCL) who aren’t eligible for transplant.

The addition of brentuximab vedotin to standard chemotherapy achieved a 41% reduction in the risk of death in patients with advanced-stage Hodgkin lymphoma in the ECHELON-1 study.

An expert explains the options for patients with DLBCL who develop chemorefractory disease in second-line treatment.

Matthew Lunning, DO, FACP, presents the case of a 64-year-old man with diffuse large B-cell lymphoma (DLBCL) and shares his initial impressions.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

The FDA has granted priority review to an approval application for mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma.

Experts discuss the newest approaches for treating patients with diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Manali Kamdar, discussed the recent FDA approval of lisocabtagene maraleucel for the treatment of patients with relapsed or refractory large B-cell lymphoma, and how community oncologists should approach patient referrals and post-treatment care.

Grzegorz S. Nowakowski, MD, presents the case of a woman with relapsed DLBLC and provides his initial impressions.

In a phase 1 clinical trial, treatment with GFH009 showed early signal s of efficacy in patients with advanced relapsed or refractory lymphoma and acute myeloid leukemia.

The FDA has granted orphan drug designation to MB-106, for the treatment of patients with Waldenstrom macroglobulinemia. The agent is being investigated in a phase 1/2 clinical trial.

Patients with relapsed/refractory diffuse large B-cell lymphoma who benefit most from novel therapies vs patients who would likely do well with standard treatment were identified among all curatively treated patients in Sweden from 2007 to 2014.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Clinically meaningful efficacy seen with epcoritamab in patients with highly refractory large B-cell lymphoma, according to data from the phase 2 EPCORE NHL-1 clinical trial.

Results from JACKPOT8 presented during the 2022 EHA Congress show that golidocitnib has encouraging anti-tumor efficacy and tolerable safety in patients with relapsed or refractory peripheral T-cell lymphoma.